BridgeBio Reaches Voluntary U.S. Government Deal to Expand Medicaid Access to Attruby
BBIO sits 58% above its 52-week low of $48.78 on light trading volume (0.4× avg).
Summary
BridgeBio announced a voluntary agreement with the U.S. government to expand Medicaid access to Attruby via the GENEROUS Model, with no future pricing mandates and no impact on its ForgingBridges copay program.
Key Events · Product Development and Regulatory · BBIO
-
Voluntary U.S. Government Pricing Agreement
BridgeBio entered a voluntary agreement with the U.S. government to expand Medicaid access to Attruby through the GENEROUS Model, with no future pricing mandates and continued Medicare Part D coverage.
-
Orphan Indication Exclusion
The company expects its pricing commitment to exclude medicines approved exclusively for orphan indications, protecting its rare-disease pipeline economics.
-
No Impact on ForgingBridges
The agreement does not affect ForgingBridges, BridgeBio's copay assistance program that can reduce out-of-pocket costs to as little as $0 per month for qualifying patients.
-
Confidential Terms
Specific terms of the agreement remain confidential, limiting visibility into the financial impact on Attruby pricing and margins.
Analysis · BBIO · Life Sciences
A voluntary agreement with the U.S. government will expand Medicaid access to Attruby, BridgeBio's approved ATTR-CM drug, through the GENEROUS Model, while Medicare Part D coverage continues without future pricing mandates. The deal aims to lower drug costs for Americans without jeopardizing rare-disease innovation, and the company expects its pricing commitment to exclude medicines approved exclusively for orphan indications. Specific terms remain confidential, but the agreement removes a key regulatory overhang for BridgeBio's commercial portfolio and signals a cooperative stance with the administration on drug pricing.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BBIO was trading at $77.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.1B. The 52-week trading range was $48.78 to $93.42. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.